{"product_id":"daiichisankyo-business-model-canvas","title":"Daiichi Sankyo Business Model Canvas","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper orange\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Magnifier-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eR\u0026amp;D-driven global biopharma: Business Model Canvas snapshot for investors and strategists\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eUnlock the strategic blueprint behind Daiichi Sankyo with our concise Business Model Canvas that maps value propositions, key partners, revenue streams and competitive advantages. This snapshot shows how R\u0026amp;D-led innovation and global alliances drive growth and market resilience. Purchase the full, editable Canvas (Word \u0026amp; Excel) for detailed, section-by-section analysis to inform investors, consultants, and strategists.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eP\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eartnerships\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper green\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAcademic research alliances\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eCollaborations with universities and research institutes accelerate discovery in oncology and cardiovascular-renal science, leveraging academic expertise to access novel biology. Joint labs and sponsored studies expand access to emerging targets and modalities, while co-authorship and data sharing de-risk early research. These alliances help fill pipeline gaps and validate mechanisms of action.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eBiotech co-development deals\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003ePartnerships with biotechs give Daiichi Sankyo access to cutting-edge platforms, novel biologics, and ADC technologies that complement its internal pipelines. Co-development deals allow shared costs, risks, and milestone economics, aligning incentives across partners. In-licensing accelerates time-to-market by augmenting R\u0026amp;D capacity and filling therapeutic gaps. Out-licensing non-core assets monetizes innovation and focuses resources on strategic priorities.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eContract manufacturing organizations\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eCMOs and CDMOs enable Daiichi Sankyo to scale biologics, sterile fill-finish and specialized production, complementing in-house sites; the global CDMO market was about $60 billion in 2024, underscoring available capacity. Flexible external capacity mitigates supply risk and accelerates global launches, with tech transfers and regular GMP audits ensuring quality. The network smooths volatility, supporting rapid ramp-up for peak demand.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eClinical trial networks \u0026amp; CROs\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eGlobal CROs and site networks enable Daiichi Sankyo to run rapid, compliant multi-country trials; the global CRO market reached about $65 billion in 2024, supporting patient recruitment, data management and pharmacovigilance that compress timelines and raise success rates. Real-world evidence partners, in a RWE market ~4.2 billion in 2024, strengthen post-marketing outcomes data.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eMarket size (2024): CROs ~$65B\u003c\/li\u003e\n\u003cli\u003eRWE market (2024): ~$4.2B\u003c\/li\u003e\n\u003cli\u003eServices: recruitment, data mgmt, PV\u003c\/li\u003e\n\u003cli\u003eImpact: faster timelines, higher success rates\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRegulatory \u0026amp; market access partners\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eRegulatory and market-access partners — local regulatory consultants and HTA experts — expedite approvals and reimbursement, shaping launch and pricing strategy for 2024 programs. Health economics partners build value dossiers and outcomes models to secure formulary access. Distribution partners ensure compliant cold-chain and last-mile delivery. Alliances with patient groups inform trial design and access programs.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eLocal regulatory \u0026amp; HTA consultants\u003c\/li\u003e\n\u003cli\u003eHealth economics \u0026amp; outcomes modeling\u003c\/li\u003e\n\u003cli\u003eCold-chain distribution partners\u003c\/li\u003e\n\u003cli\u003ePatient-group alliances\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAcademic and biotech alliances speed oncology and CVR discovery; CDMOs\/CROs scale trials \u0026amp; access\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eAcademic and biotech alliances accelerate oncology and CVR discovery, de-risk early R\u0026amp;D and fill pipeline gaps.\u003c\/p\u003e\n\u003cp\u003eCDMOs\/CROs scale manufacturing and trials; CRO market ~$65B (2024), CDMO ~$60B (2024), RWE ~$4.2B (2024).\u003c\/p\u003e\n\u003cp\u003eRegulatory, HTA, distribution and patient-group partners secure approvals, reimbursement and global access.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003ePartner\u003c\/th\u003e\n\u003cth\u003e2024 metric\u003c\/th\u003e\n\u003cth\u003eImpact\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eCDMO\/CRO\u003c\/td\u003e\n\u003ctd\u003e$60B\/$65B\u003c\/td\u003e\n\u003ctd\u003eScale, speed\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRWE\u003c\/td\u003e\n\u003ctd\u003e$4.2B\u003c\/td\u003e\n\u003ctd\u003eOutcomes evidence\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-includes\"\u003e\n\u003ch2\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Word Icon\"\u003e\n\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eA comprehensive Business Model Canvas tailored to Daiichi Sankyo’s pharmaceutical strategy, covering all 9 BMC blocks with detailed customer segments, channels, value propositions, revenue and cost structures. Ideal for presentations and investor discussions, it includes competitive advantages, linked SWOT analysis and actionable insights reflecting real-world operations and growth plans.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"plus-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Plus-Icon.svg\" alt=\"Plus Icon\"\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Excel Icon\"\u003e\n\u003cstrong\u003eCustomizable Excel Spreadsheet\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eHigh-level, editable Business Model Canvas for Daiichi Sankyo that condenses R\u0026amp;D, commercialization, and partnership strategies into a single-page snapshot to quickly relieve strategic planning pain points. Shareable and ready for team collaboration, it saves hours of structuring and supports fast executive summaries or side-by-side comparisons.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eA\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003ectivities\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eTargeted R\u0026amp;D in priority areas\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eDiscovery and development concentrate on two priority areas: oncology and cardiovascular-renal, with oncology programs exemplified by the Enhertu collaboration. Biomarker-driven patient selection is central to trial design, improving technical success and regulatory predictability. Preclinical through Ph3 execution is streamlined for speed and quality using cross-functional teams and adaptive trial designs. Portfolio reviews prioritize assets showing robust clinical signals and clear commercial pathways.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eClinical development \u0026amp; medical affairs\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eDesign and run pivotal, global randomized trials to establish safety and efficacy for regulatory approvals and guideline adoption. Generate robust clinical and health-economic evidence for regulators, payers, and clinicians to support reimbursement and formulary decisions. Provide medical education and peer-reviewed publications to disseminate data responsibly while continuous safety monitoring and risk management span the product lifecycle.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eManufacturing \u0026amp; quality operations\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eScale reliable GMP production for small molecules, biologics, and ADCs across Daiichi Sankyo’s Japan, US and EU manufacturing network, with tech transfer programs to enable efficient global supply. Implement robust quality systems, validation and continuous improvement to meet regulatory standards and reduce batch deviations. Secure raw materials and dual-source critical components to maintain supply continuity and minimize disruption.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRegulatory, access, and pricing strategy\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cpprepare regulatory dossiers manage inspections and multi-region approvals leveraging fda standard review timelines months ema centralized procedure days build heor year budget impact models to support hta decisions negotiate pricing tenders value-based contracts maintain compliance across evolving policies.\u003e\n\u003cp\u003e\u003c\/p\u003e\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eRegulatory timelines: FDA 10 months, EMA 210 days\u003c\/li\u003e\n\u003cli\u003eHEOR: 1–5 year budget impact horizon\u003c\/li\u003e\n\u003cli\u003eContracts: pricing, tenders, value-based\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/pprepare\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCommercialization \u0026amp; lifecycle management\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eLaunch planning, brand strategy and omnichannel engagement drove uptake for Daiichi Sankyo’s oncology franchise, centered on Enhertu in partnership with AstraZeneca, with global label expansions through 2024 broadening patient reach.\u003c\/p\u003e\n\u003cp\u003ePost-approval studies and line extensions sustained value; indication expansions and real-world evidence programs increased prescribing and reimbursement access in key markets by 2024.\u003c\/p\u003e\n\u003cp\u003ePatient support programs improved adherence and outcomes via nurse support, financial assistance and digital tools.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eLaunch planning: global commercialization of Enhertu\u003c\/li\u003e\n\u003cli\u003eLifecycle: post-approval studies \u0026amp; line extensions\u003c\/li\u003e\n\u003cli\u003eIndication expansion: broader patient populations in 2024\u003c\/li\u003e\n\u003cli\u003ePatient support: adherence programs, digital engagement\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eBiomarker‑driven oncology \u0026amp; CV‑renal: FDA \u003cstrong\u003e10\u003c\/strong\u003emo, EMA 210d\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eDiscovery and development focus on oncology and CV‑renal with biomarker‑guided trials and cross‑functional, adaptive Ph1–Ph3 execution. Global regulatory strategy uses FDA standard review (10 months) and EMA centralized procedure (210 days) with HEOR 1–5 year budget models. Manufacturing spans Japan, US and EU with GMP for small molecules, biologics and ADCs; launches and lifecycle management (Enhertu label expansions through 2024) drive commercialization.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eActivity\u003c\/th\u003e\n\u003cth\u003eFact\/Metric (2024)\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eRegulatory\u003c\/td\u003e\n\u003ctd\u003eFDA 10 months; EMA 210 days\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eHEOR horizon\u003c\/td\u003e\n\u003ctd\u003e1–5 years\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eManufacturing regions\u003c\/td\u003e\n\u003ctd\u003eJapan, US, EU\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eKey product\u003c\/td\u003e\n\u003ctd\u003eEnhertu label expansions through 2024\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003ePreview Before You Purchase\u003c\/span\u003e\u003cbr\u003e Business Model Canvas\u003c\/h2\u003e\n\u003cp\u003eThe Daiichi Sankyo Business Model Canvas you’re previewing is the exact deliverable—not a mockup or sample—and contains the same structured content you’ll receive after purchase. When you complete your order, you’ll get the full, editable document in Word and Excel formats, ready for presentation, editing, or sharing. No hidden pages, no filler—what you see is what you’ll own.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eR\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eesources\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Resources-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eScientific talent \u0026amp; IP\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eExperienced researchers, clinicians and regulatory experts—supported by ~16,000 global employees (2024)—anchor Daiichi Sankyo’s innovation engine. A strong patent estate protects core assets and platform technologies, while deep know-how in ADCs and targeted therapies differentiates the pipeline. Continuous upskilling programs and collaborations sustain the company’s competitive advantage and regulatory readiness.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Resources-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eClinical and real-world data\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eBy 2024 Daiichi Sankyo integrates trial datasets, registries and real‑world evidence to guide portfolio and clinical development decisions. Biomarker and companion diagnostic data refine patient selection and enrich pivotal trials for targeted therapies. Scalable data platforms enable advanced analytics, predictive modeling and external control arms. Robust evidence packages support regulatory approvals and payer reimbursement negotiations.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Resources-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Resources-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eManufacturing infrastructure\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eFacilities for API, biologics and specialized modalities—operating over 15 manufacturing and R\u0026amp;D sites globally as of 2024—give Daiichi Sankyo direct control over production. Robust quality systems meet GMP and global regulatory standards, ensuring reliability. Integrated supply chain capabilities secure raw materials and distribution across markets. Scalable capacity supports rising global demand for Enhertu and other specialty assets.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Resources-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eStrategic partnerships portfolio\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eAlliances with biotechs, academia and service providers expand Daiichi Sankyo’s capabilities; Enhertu, co‑developed with AstraZeneca, secured approvals in the US, EU and Japan by 2024, illustrating partner-enabled reach. Co‑development and in‑licensing diversify pipeline risk while governance frameworks (joint steering committees, milestone‑driven agreements) manage programs effectively and the broad network accelerates innovation.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eEnhertu — co‑dev w\/ AstraZeneca; approvals: US, EU, JP (2024)\u003c\/li\u003e\n\u003cli\u003eCo‑dev + in‑licensing = pipeline diversification\u003c\/li\u003e\n\u003cli\u003eGovernance: joint steering, milestone governance\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Resources-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGlobal commercial footprint\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eGlobal commercial footprint: Daiichi Sankyo leverages over 30 country affiliates with dedicated key-account teams and payer relations to drive formulary access and uptake; in 2024 commercial focus concentrated on oncology and rare disease franchises. Digital channels expanded clinician and patient engagement, supporting market insights that guide allocation of sales and medical resources. Established brands and partner co-commercialization strengthen payer and provider relationships.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003ecountry affiliates: over 30\u003c\/li\u003e\n\u003cli\u003efocus: oncology\/rare disease\u003c\/li\u003e\n\u003cli\u003edigital reach: clinician\/patient channels\u003c\/li\u003e\n\u003cli\u003edrivers: key-account teams, payer relations\u003c\/li\u003e\n\u003cli\u003einsights: market data guides resource allocation\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Resources-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGlobal R\u0026amp;D with \u003cstrong\u003e~16,000\u003c\/strong\u003e staff, 15+ sites, 30+ affiliates\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eExperienced R\u0026amp;D and regulatory teams supported by ~16,000 employees (2024) and proprietary IP\/ADC know‑how drive innovation. Integrated real‑world and biomarker data inform trials and reimbursement. 15+ manufacturing\/R\u0026amp;D sites and 30+ country affiliates ensure supply and commercialization; partnerships (eg Enhertu co‑dev with AstraZeneca; approvals US\/EU\/JP 2024) expand reach.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003e2024\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eEmployees\u003c\/td\u003e\n\u003ctd\u003e~16,000\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSites\u003c\/td\u003e\n\u003ctd\u003e15+\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCountry affiliates\u003c\/td\u003e\n\u003ctd\u003e30+\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eKey asset\u003c\/td\u003e\n\u003ctd\u003eEnhertu (US\/EU\/JP)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eV\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003ealue Propositions\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Value-Propositions-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eInnovative therapies for high unmet need\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eDaiichi Sankyo delivers first‑ or best‑in‑class medicines in oncology and CV‑renal, exemplified by Enhertu, approved in major markets including the US, EU and Japan and available in over 20 countries as of 2024. Precision approaches target tumors or renal\/CV pathways to improve outcomes and reduce unnecessary toxicity versus non‑selective therapies. Robust randomized and real‑world data have driven clinical adoption and guideline inclusion, expanding patient access to life‑changing options.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Value-Propositions-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePrecision and targeted delivery\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eBiomarker- and ADC-driven modalities selectively target diseased cells, underpinning Daiichi Sankyo’s Precision and targeted delivery value proposition; by 2024 there were over a dozen ADC approvals demonstrating proof of concept. Improved therapeutic index from targeted delivery enhances the efficacy-safety balance, enabling higher response rates with fewer off-target toxicities. Companion diagnostics guide appropriate use—used in an increasing share of oncology approvals in 2024—allowing clinicians to personalize treatment pathways and optimize outcomes.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Value-Propositions-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Value-Propositions-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eReliable global supply and quality\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eDaiichi Sankyo leverages strong manufacturing and QA across over 20 countries and a global workforce of about 16,000 (2024) to maintain consistent product availability. Redundant regional sourcing and multiple production sites reduce shortage risk and support continuity. Robust cold-chain logistics and validated distribution networks protect product integrity so providers and patients can trust ongoing care.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Value-Propositions-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHealth economic value\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eHealth economic value: 2024 real-world analyses show ~22% fewer hospitalizations and improved survival versus standard care, translating to approximately $2,500 avoided cost per patient-year; demonstrated cost-effectiveness supports formulary listings and reimbursement negotiations, while outcomes evidence underpins value-based contracting and gives payers a more predictable budget impact.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e22% fewer hospitalizations (2024 real-world)\u003c\/li\u003e\n\u003cli\u003e$2,500 avoided cost per patient-year\u003c\/li\u003e\n\u003cli\u003eEnables value-based contracts\u003c\/li\u003e\n\u003cli\u003ePredictable payer budget impact\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Value-Propositions-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eComprehensive support services\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eComprehensive support services—patient assistance, adherence tools, and nurse helplines—improve patient experience and help clinicians manage therapy; WHO estimates adherence to long-term therapies averages about 50% in high-income countries. Medical education programs provide clinicians with evidence and guidance; access programs shorten initiation timelines and deliver end-to-end support for all stakeholders.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003ePatient assistance: reduces financial barriers\u003c\/li\u003e\n\u003cli\u003eAdherence tools: address ~50% adherence gap (WHO)\u003c\/li\u003e\n\u003cli\u003eNurse helplines: improve engagement and retention\u003c\/li\u003e\n\u003cli\u003eAccess programs: expedite therapy start and coordination\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Value-Propositions-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePrecision ADCs and diagnostics: \u003cstrong\u003e22%\u003c\/strong\u003e fewer hospitalizations, save \u003cstrong\u003e$2,500\u003c\/strong\u003e\/pt-yr\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eDaiichi Sankyo delivers first‑\/best‑in‑class oncology and CV‑renal medicines (Enhertu in 20+ countries by 2024), precision ADCs and companion diagnostics improving efficacy\/safety, HEOR showing 22% fewer hospitalizations and ~$2,500 avoided cost\/patient‑yr, and global manufacturing with ~16,000 workforce plus patient support to boost adherence.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue (2024)\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eCountries\u003c\/td\u003e\n\u003ctd\u003e20+\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eWorkforce\u003c\/td\u003e\n\u003ctd\u003e~16,000\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eHospitalization reduction\u003c\/td\u003e\n\u003ctd\u003e22%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAvoided cost\/patient‑yr\u003c\/td\u003e\n\u003ctd\u003e$2,500\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eADC approvals\u003c\/td\u003e\n\u003ctd\u003e12+\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eC\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eustomer Relationships\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Relationships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eEvidence-driven engagement\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003ePeer-reviewed publications, congress symposia (ASCO 2024 attendance ≈42,000) and targeted MSL interactions build trust by disseminating robust data; transparent sharing of trial datasets and safety findings supports informed prescribing decisions. All scientific exchange is non-promotional and compliance-driven, preserving long-term credibility that sustains adoption and market uptake.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Relationships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eKey account management\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eDedicated key account teams serve hospitals, oncology centers and IDNs, aligning with Daiichi Sankyo’s 2024 oncology commercial strategy. Tailored solutions address formulary inclusion, clinical pathways and operational workflows to support product access. Contracting and tender support streamline procurement and reduce time-to-supply. Deeper relationships in 2024 increased account retention and repeat contracting velocity.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Relationships-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Relationships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePatient-centric programs\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eEnrollment assistance and copay support reduce access barriers, with a 2024 IQVIA analysis showing patient support programs can lower treatment abandonment and improve initiation rates by about 11%.\u003c\/p\u003e\n\u003cp\u003eAdherence tools and tailored education delivered via apps and nurse coaching raise persistence and clinical outcomes, correlating with reported adherence gains in real-world 2024 studies.\u003c\/p\u003e\n\u003cp\u003ePharmacovigilance systems ensure proactive safety follow-up and case reporting, supporting regulatory compliance and risk mitigation in 2024 post-marketing surveillance frameworks.\u003c\/p\u003e\n\u003cp\u003eClosed-loop feedback from patient surveys and claims data in 2024 drives iterative service improvements and targets resource allocation to higher-impact interventions.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Relationships-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDigital omnichannel touchpoints\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eDigital omnichannel touchpoints—portals, webinars, and e-detailing—deliver on-demand clinical and product information while CRM-guided outreach personalizes content based on provider segmentation; remote support complements field teams to cover 24\/7 needs. In 2024 Daiichi Sankyo accelerated digital engagement, reporting a 30% increase in virtual interactions year-over-year, with analytics used to optimize visit timing and content.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003ePortals: on-demand clinical dossiers and patient support\u003c\/li\u003e\n\u003cli\u003eWebinars\/e-detailing: scalable HCP education\u003c\/li\u003e\n\u003cli\u003eCRM-guided outreach: personalized messaging\u003c\/li\u003e\n\u003cli\u003eRemote support: supplements field force coverage\u003c\/li\u003e\n\u003cli\u003eData analytics: optimization of engagement cadence (2024 uplift 30%)\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Relationships-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eStakeholder partnerships\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eCollaboration with advocacy groups and guideline bodies amplifies Daiichi Sankyo’s impact by aligning patient priorities with development and access strategies, while KOL input shapes evidence-generation and publication plans to support guideline adoption. Health system partnerships pilot innovative care models that integrate therapies into care pathways, and trust grows through transparent shared goals and co-designed outcomes.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eAdvocacy alignment: patient-centered priorities\u003c\/li\u003e\n\u003cli\u003eKOL-driven evidence planning\u003c\/li\u003e\n\u003cli\u003eHealth-system pilots: care pathway integration\u003c\/li\u003e\n\u003cli\u003eTrust via shared goals and transparent metrics\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Relationships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eScience-led KOL \u0026amp; access teams boost adoption; virtual HCPs \u003cstrong\u003e+30%\u003c\/strong\u003e, abandonment \u003cstrong\u003e≈11%\u003c\/strong\u003e\n\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eScientific exchange (peer-reviewed data, MSLs; ASCO 2024 attendance ≈42,000) builds trust; KOLs and guideline alignment drive adoption. Key account teams, contracting and patient access programs enhance formulary inclusion and retention. Digital omnichannel plus adherence support lifted virtual HCP interactions +30% and reduced treatment abandonment ~11% in 2024.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003e2024\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eASCO attendance\u003c\/td\u003e\n\u003ctd\u003e≈42,000\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eVirtual interactions uplift\u003c\/td\u003e\n\u003ctd\u003e+30%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePatient support effect on initiation\u003c\/td\u003e\n\u003ctd\u003e≈+11%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eC\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003ehannels\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Channels-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSpecialty sales force\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eFocused specialty teams engage oncologists, cardiologists and hospital pharmacy to support complex Daiichi Sankyo therapies, using scientific detailing aligned with evidence and guidelines. Field support coordinates patient access, prior authorization and HUB services to accelerate starts. The high-touch model matches therapies with complex administration and monitoring. Specialty medicines accounted for roughly 50% of US drug spending in 2023–2024.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Channels-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDistributor and wholesale networks\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eGlobal wholesalers and specialty distributors in over 20 countries ensure Daiichi Sankyo products reach commercial and hospital channels. Cold-chain and controlled distribution follow GDP\/WHO standards, aligning with the ~USD 20 billion global pharmaceutical cold-chain market in 2024. Public tenders supply many hospitals and national systems, while efficient networks and tender participation help cut stockouts and maintain continuity of care.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Channels-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Channels-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDigital platforms and portals\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eHCP portals provide 24\/7 access to materials, samples and ordering workflows, supporting field teams and compliant digital rep interactions in 2024. Virtual education scales scientific updates across global HCP cohorts via on-demand modules and live webinars. Patient sites enable support program enrollment and adherence tools, while embedded analytics track engagement, prescribing signals and unmet needs in real time.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Channels-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHospitals and infusion centers\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eHospitals and infusion centers serve as a direct channel for Daiichi Sankyo’s infused and specialty-administered products, with pathway inclusion driving utilization; in 2024 specialty medicines represented about 50% of US drug spend, concentrating demand in hospital-administered care. On-site clinical support ensures proper handling and adherence, while real-world feedback from centers informs product, safety and access improvements.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eDirect channel\u003c\/li\u003e\n\u003cli\u003ePathway-driven uptake\u003c\/li\u003e\n\u003cli\u003eOn-site handling \u0026amp; support\u003c\/li\u003e\n\u003cli\u003eReal-world feedback loops\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Channels-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCompanion diagnostic partners\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eCompanion diagnostic labs and kit providers identify eligible patients; as of 2024 there are over 40 FDA-cleared companion diagnostic tests, supporting precision use of Daiichi Sankyo therapies. Integrated testing streamlines initiation, often cutting time-to-treatment by up to one week, while co-promotion aligns testing and therapy uptake to raise appropriate prescribing. Faster diagnosis supports better outcomes and higher treatment value realization.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eCDx tests: over 40 FDA-cleared (2024)\u003c\/li\u003e\n\u003cli\u003eMarket size: ~USD 6B (2024 est.)\u003c\/li\u003e\n\u003cli\u003eTime-to-treatment: up to 1 week faster\u003c\/li\u003e\n\u003cli\u003eUptake boost: double-digit % gains in appropriate prescribing\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Channels-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSpecialty teams, hub services and CDx accelerate uptake and supply of complex oncology therapies\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eSpecialty-focused field teams, HUB services and HCP portals drive uptake for complex Daiichi Sankyo therapies, matching high-touch support to hospital and infusion channels. Global wholesalers, cold-chain logistics and tender participation sustain supply across 20+ countries. Companion diagnostics (40+ FDA-cleared in 2024) speed initiation and improve appropriate prescribing.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003e2024 value\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eUS specialty drug spend\u003c\/td\u003e\n\u003ctd\u003e~50%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCold-chain market\u003c\/td\u003e\n\u003ctd\u003e~USD 20B\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eFDA-cleared CDx\u003c\/td\u003e\n\u003ctd\u003e\u0026gt;40\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCDx market\u003c\/td\u003e\n\u003ctd\u003e~USD 6B\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eC\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eustomer Segments\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Segments-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eOncologists and cancer centers\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eOncologists and cancer centers are the primary prescribers for targeted and ADC therapies, influencing formulary decisions and clinical adoption; by 2024 regulators have approved more than 10 ADCs, increasing clinician demand for head-to-head and long-term safety data. They require robust efficacy and safety evidence, value real-world outcomes and guideline alignment, and prioritize patient access programs, reimbursement support, and hub services to expedite treatment initiation.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Segments-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCardiologists and nephrologists\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eCardiologists and nephrologists manage CV‑renal patients on complex polypharmacy and prioritize therapies shown to improve survival and reduce events—SGLT2 trials report ~30–44% relative risk reductions in HF hospitalization\/CKD progression. They demand unambiguous dosing and monitoring protocols and consider cost‑effectiveness (US payer benchmark ~100,000 USD\/QALY) when adopting new agents.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Segments-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Segments-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHospitals and health systems\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eHospital formulary and P\u0026amp;T committees drive inclusion and clinical pathways, prioritizing total cost of care and operational efficiency; they demand reliable supply, flexible contracting and outcomes data for decisions. By 2024, value‑based contracts remained under 5% of US drug spend, so real‑world outcomes evidence is critical for uptake.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Segments-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePayers and HTA bodies\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003ePayers and HTA bodies demand robust clinical and economic evidence for coverage decisions, requiring randomized trials plus budget-impact and cost-effectiveness models; by 2024 value-based contracts and risk-sharing arrangements covered an increasing share of oncology and rare-disease launches to control spend and link payment to outcomes.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eCoverage hinge: clinical + economic value\u003c\/li\u003e\n\u003cli\u003eRequire: budget-impact and CEA models\u003c\/li\u003e\n\u003cli\u003eTrend 2024: rising risk-sharing\/value contracts\u003c\/li\u003e\n\u003cli\u003ePriority: predictable utilization and measurable outcomes\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Segments-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePatients and caregivers\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003ePatients and caregivers gain improved survival and quality of life from therapies like trastuzumab deruxtecan (DESTINY‑Breast03 PFS HR 0.28), but need access, affordability, and clear education on treatment pathways. They prioritize manageable side effects and robust support services; advocacy groups increasingly shape research priorities and trial design.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eBenefit: survival gain (DESTINY‑B03 HR 0.28)\u003c\/li\u003e\n\u003cli\u003eNeeds: access, affordability, education\u003c\/li\u003e\n\u003cli\u003eValue: side‑effect management, support\u003c\/li\u003e\n\u003cli\u003eInfluence: advocacy guides research\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Segments-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eOncology fuels ADC uptake; cardiology backs SGLT2 survival gains; payers demand RWE\/value\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eOncologists\/cancer centers drive ADC uptake; by 2024 \u0026gt;10 ADCs approved, requiring long‑term safety, RWE and access programs. Cardiologists\/nephrologists prioritize survival\/HF benefit (SGLT2 RRR ~30–44%) and cost‑effectiveness (~100,000 USD\/QALY). Payers\/P\u0026amp;T demand RCTs plus budget‑impact\/CEA; value‑based contracts \u0026lt;5% of US drug spend (2024).\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eSegment\u003c\/th\u003e\n\u003cth\u003eKey metric (2024)\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eOncology\u003c\/td\u003e\n\u003ctd\u003e\u0026gt;10 ADC approvals\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCV‑renal\u003c\/td\u003e\n\u003ctd\u003eSGLT2 RRR 30–44%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePayers\/P\u0026amp;T\u003c\/td\u003e\n\u003ctd\u003eVBC \u0026lt;5% drug spend\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePatients\u003c\/td\u003e\n\u003ctd\u003eDESTINY‑B03 HR 0.28\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eC\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eost Structure\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Cost-Structure-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eR\u0026amp;D and clinical trial spend\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eR\u0026amp;D and clinical trial spend at Daiichi Sankyo is concentrated from discovery through Phase III and post-approval studies, with site fees, CROs and advanced biomarker testing as primary cost drivers; Daiichi Sankyo reported JPY 189.7 billion in R\u0026amp;D expenses in FY2023 (ended March 2024).\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Cost-Structure-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eManufacturing and quality costs\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eFacility operations, validation and CMO fees are major line items for Daiichi Sankyo, especially as biologics and ADCs generally carry higher COGS—industry norms run about 30–40% of product revenue for biologics vs 10–20% for small molecules. ADCs can increase complexity and unit COGS by roughly 2–3x. Redundant supply chains add resilience but typically raise manufacturing expense ~10–15%, and ongoing QA\/validation consumes another ~5–8% of manufacturing spend.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Cost-Structure-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Cost-Structure-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCommercial and market access\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eSales force, medical affairs and omnichannel investments drive scale-heavy cost bases; industry data show commercial spend averaged about 24% of revenue in 2023–24 (IQVIA), underlining Daiichi Sankyo's need for large-scale teams. HEOR, pricing and tendering incur specialized staffing and consultancy fees, while patient support programs can represent single-digit to low-double-digit percent shares of launch budgets. Launches concentrate expenditures upfront, often front-loading 50–70% of first‑year commercial investment. \u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Cost-Structure-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRegulatory and compliance\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eSubmission preparation, inspections, and pharmacovigilance are continuous cost drivers for Daiichi Sankyo; data privacy and promotional compliance require dedicated IT and governance systems; legal and IP protection add significant overhead; global operations multiply jurisdictional complexity and localized compliance costs.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eRegulatory continuity\u003c\/li\u003e\n\u003cli\u003ePV \u0026amp; inspections\u003c\/li\u003e\n\u003cli\u003eData \u0026amp; promo systems\u003c\/li\u003e\n\u003cli\u003eLegal\/IP overhead\u003c\/li\u003e\n\u003cli\u003eGlobal complexity\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Cost-Structure-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePartnership and licensing payments\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eUpfronts, milestones and royalties compensate collaborators; major oncology deals in 2024 show upfronts and milestones can total tens to hundreds of millions, while royalties often fall in the mid-single to low-double digit percentiles.\u003c\/p\u003e\n\u003cp\u003eCo-development cost-sharing shifts R\u0026amp;D cash flows and capital timing; option fees (commonly $1–10M) secure future rights, and deal management adds integration and regulatory coordination costs.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eUpfronts\/milestones: tens–hundreds of $M\u003c\/li\u003e\n\u003cli\u003eRoyalties: mid-single to low-double digits %\u003c\/li\u003e\n\u003cli\u003eOption fees: $1–10M\u003c\/li\u003e\n\u003cli\u003eIntegration: program management and regulatory costs\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Cost-Structure-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eR\u0026amp;D \u0026amp; trials drove costs: JPY 189.7bn FY2023; biologics COGS 30–40%; commercial ~24% rev\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eR\u0026amp;D and clinical trials dominate costs—JPY 189.7 billion R\u0026amp;D in FY2023 (ended Mar 2024)—with CROs, site fees and biomarker testing as primary drivers. Manufacturing\/COGS higher for biologics\/ADCs (30–40% revenue; ADCs 2–3x unit COGS), plus 10–15% premium for redundant supply chains. Commercial spend (~24% revenue in 2023–24) and global compliance, PV, legal\/IP add recurring overhead; partnerships bring upfronts\/milestones and royalties.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eR\u0026amp;D FY2023\u003c\/td\u003e\n\u003ctd\u003eJPY 189.7 bn\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eBiologics COGS\u003c\/td\u003e\n\u003ctd\u003e30–40% rev\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCommercial spend\u003c\/td\u003e\n\u003ctd\u003e~24% rev\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eUpfronts\/milestones\u003c\/td\u003e\n\u003ctd\u003etens–hundreds $M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eR\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eevenue Streams\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Revenue-Streams-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePrescription drug sales\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003ePrescription drug sales form core revenue for Daiichi Sankyo, led by oncology (notably Enhertu) and CV-renal portfolios; FY2024 consolidated pharma sales were about ¥1,062.5 billion, with oncology driving year-over-year growth. The mix spans hospital-administered biologics and retail-dispensed small molecules, supporting margin diversification. Geographic diversification across Japan, US and Europe balances regional risk. Active lifecycle management and label expansions sustain pipeline-led growth.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Revenue-Streams-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eMilestones and collaboration income\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eMilestones and collaboration income for Daiichi Sankyo include partner payments tied to development and regulatory events, with 2024 disclosures showing continued milestone receipts from oncology alliances. Sales milestones add upside at launch while cost-sharing provisions reduce net R\u0026amp;D spend on partnered programs. Co-promotion fees and tiered royalties further supplement revenue, diversifying cash flow beyond direct product sales.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Revenue-Streams-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Revenue-Streams-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRoyalties and out-licensing\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eRoyalties from licensed assets and technologies provide recurring income for Daiichi Sankyo, underpinning collaboration revenue reported in 2024. Out-licensing non-core programs monetizes R\u0026amp;D spend and accelerates partner-driven development. Platform licensing extends reach into new markets and therapeutic areas, and the resulting predictable cash flows support reinvestment into priority pipelines.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Revenue-Streams-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCompanion diagnostics and services\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eRevenues from companion diagnostics and testing support in 2024 include fees and milestone payments from CDx partnerships tied to therapies like trastuzumab deruxtecan, with testing services often bundled into treatment contracts. Value-added services and lab support are packaged with drug sales; data services and RWE collaborations open licensing and analytics revenue streams. These offerings accelerate diagnosis-to-treatment time and enhance therapy adoption.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eCDx partnerships — milestone and service fees\u003c\/li\u003e\n\u003cli\u003eBundled testing — supports patient uptake\u003c\/li\u003e\n\u003cli\u003eData\/RWE — analytics, licensing revenue\u003c\/li\u003e\n\u003cli\u003eMarket impact 2024 — faster adoption of ENHERTU-linked testing\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Revenue-Streams-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eTenders and government contracts\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eInstitutional sales via national and regional tenders provide Daiichi Sankyo with predictable, large-volume contracts. Volume-based pricing secures recurring demand and supports scale, contributing to consolidated revenue of about ¥1.1 trillion in FY2023. Strict compliance and supply reliability are critical to win and retain public-sector contracts and enable deeper penetration of public health systems.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eInstitutional tenders: national\/regional\u003c\/li\u003e\n\u003cli\u003eVolume pricing: secures recurring demand\u003c\/li\u003e\n\u003cli\u003eCompliance \u0026amp; supply: contract-critical\u003c\/li\u003e\n\u003cli\u003eEnables public health penetration\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Revenue-Streams-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eFY2024 pharma: prescription sales ¥1,062.5B fuel oncology and CV-renal growth\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003ePrescription drug sales remain core for Daiichi Sankyo, with FY2024 consolidated pharma sales of ¥1,062.5 billion driven by oncology and CV-renal portfolios. Milestones, collaboration income and royalties provided recurring upside in 2024, often disclosed as material but not fully itemized. Companion diagnostics, testing and institutional tenders support adoption and volume-based, predictable revenue streams.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eRevenue stream\u003c\/th\u003e\n\u003cth\u003e2024 figure \/ note\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003ePrescription drug sales\u003c\/td\u003e\n\u003ctd\u003e¥1,062.5 billion (FY2024 consolidated pharma)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eMilestones \u0026amp; collaborations\u003c\/td\u003e\n\u003ctd\u003eMaterial; amounts partner-disclosed (2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRoyalties \u0026amp; licensing\u003c\/td\u003e\n\u003ctd\u003eRecurring; disclosed within collaboration revenue 2024\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCDx\/testing \u0026amp; tenders\u003c\/td\u003e\n\u003ctd\u003eSupport adoption\/volume contracts; cited in 2024 reports\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e","brand":"PESTEL Analysis","offers":[{"title":"Default Title","offer_id":58097787765084,"sku":"daiichisankyo-business-model-canvas","price":10.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0938\/8127\/0620\/files\/daiichisankyo-business-model-canvas.png?v=1781792157","url":"https:\/\/pestel-analysis.com\/products\/daiichisankyo-business-model-canvas","provider":"PESTEL ANALYSIS","version":"1.0","type":"link"}